| Abbreviations |
|
2 | (2) |
|
Clinical Approach to Initial Choice of Antimicrobial Therapy |
|
|
4 | (55) |
|
Prophylaxis and Treatment of Organisms of Potential Use as Biological Weapons |
|
|
59 | (2) |
|
Recommended Antimicrobial Agents Against Selected Bacteria |
|
|
61 | (3) |
|
Suggested Duration of Antibiotic Therapy in Immunocompetent Patients |
|
|
64 | (1) |
|
Comparison of Antimicrobial Spectra |
|
|
65 | (6) |
|
Treatment Options for Selected Highly Resistant Bacteria |
|
|
71 | (2) |
|
Suggested Management of Suspected or Culture-Positive Community-Acquired Phenotype of Methicillin-Resistant S. Aureus (CA-MRSA) Infections |
|
|
73 | (1) |
|
Methods for Penicillin Desensitization |
|
|
74 | (1) |
|
Risk Categories of Antimicrobics in Pregnancy |
|
|
74 | (1) |
|
Selected Pharmacologic Features of Antimicrobial Agents |
|
|
75 | (5) |
|
Pharmacodynamics of Antibacterials |
|
|
79 | (1) |
|
Selected Antibacterial Agents---Adverse Reactions---Overview |
|
|
80 | (14) |
|
Antimicrobial Agents Associated with Photosensitivity |
|
|
84 | (1) |
|
Summary of Antibiotic Dosage, Side-Effects, and Cost |
|
|
85 | (8) |
|
Aminoglycoside Once-Daily and Multiple Daily Dosing Regimens |
|
|
93 | (1) |
|
Treatment of Fungal, Actinomycotic, and Nocardial Infections---Antimicrobial Agents of Choice |
|
|
94 | (16) |
|
Antifungal Drugs: Adverse Effects, Comments, Cost |
|
|
105 | (4) |
|
Summary of Suggested Antifungal Drugs Against Treatable Pathogenic Fungi |
|
|
109 | (1) |
|
Treatment of Mycobacterial Infections |
|
|
110 | (13) |
|
Dosage, Price and Selected Adverse Effects of Antimycobacterial Drugs |
|
|
120 | (3) |
|
Treatment of Parasitic Infections |
|
|
123 | (12) |
|
Dosage, Price, and Selected Adverse Effects of Antiparasitic Drugs |
|
|
132 | (2) |
|
Parasites that Cause Eosinophilia |
|
|
134 | (1) |
|
Antiviral Therapy (Non-HIV) |
|
|
135 | (32) |
|
Antiviral Drugs (Other Than Retroviral) |
|
|
147 | (4) |
|
Summary of Suggested Antiviral Agents Against Treatable Pathogenic Viruses |
|
|
151 | (1) |
|
Antiretroviral Therapy in Treatment-Naive Adults |
|
|
152 | (12) |
|
Antiretroviral Drugs and Adverse Effects |
|
|
164 | (3) |
|
Antimicrobial Prophylaxis for Selected Bacterial Infections |
|
|
167 | (10) |
|
Surgical Antibiotic Prophylaxis |
|
|
168 | (3) |
|
Antimicrobial Prophylaxis for the Prevention of Bacterial Endocarditis in Patients with Underlying Cardiac Conditions |
|
|
171 | (1) |
|
Management of Exposure to HIV-1 and Hepatitis B and C |
|
|
172 | (3) |
|
Prevention of Opportunistic Infection in Human Stem Cell Transplantation (HSCT) or Solid Organ Transplantation (SOT) for Adults with Normal Renal Function |
|
|
175 | (2) |
|
Pediatric Dosages of Selected Antibacterial Agents |
|
|
177 | (1) |
|
Dosages of Antimicrobial Drugs in Adult Patients with Renal Impairment |
|
|
178 | (7) |
|
No Dosage Adjustment with Renal Insufficiency by Category |
|
|
185 | (1) |
|
Antimicrobials and Hepatic Disease Dosage Adjustment |
|
|
185 | (1) |
|
Treatment of CAPD Peritonitis in Adults |
|
|
185 | (1) |
|
Recommended Childhood and Adolescent Immunization Schedule: United States (Includes Schedule for ages 7-18), 2007 |
|
|
186 | (11) |
|
Catch-Up Immunization Schedule For Persons Aged 4 Months--18 Years Who Start Late Or Who Are ≥ 1 Month Behind --- United States, 2007 |
|
|
189 | (2) |
|
Adult Immunization In The United States |
|
|
191 | (4) |
|
Anti-Tetanus Prophylaxis, Wound Classification, Immunization |
|
|
195 | (1) |
|
Rabies Post-Exposure Prophylaxis |
|
|
196 | (1) |
|
Selected Directory of Resources |
|
|
197 | (1) |
|
Anti-Infective Drug-Drug Interactions |
|
|
198 | (8) |
|
Drug-Drug Interactions Between Protease Inhibitors |
|
|
204 | (1) |
|
Drug-Drug Interactions Between Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIS) and Protease Inhibitors |
|
|
205 | (1) |
|
List of Generic and Common Trade Names |
|
|
206 | (2) |
| Index of Major Entities |
|
208 | |
